Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4%

AC Immune SA (NASDAQ:ACIU - Get Free Report) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totalling 796,900 shares, a decline of 7.4% from the September 30th total of 860,900 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 118,700 shares, the days-to-cover ratio is presently 6.7 days.

Institutional Trading of AC Immune

Hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC purchased a new stake in AC Immune in the 1st quarter worth about $30,000. BNP Paribas Financial Markets boosted its holdings in shares of AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock worth $33,000 after purchasing an additional 8,423 shares during the period. Silverberg Bernstein Capital Management LLC purchased a new position in AC Immune during the second quarter valued at approximately $40,000. Vanguard Capital Wealth Advisors acquired a new position in AC Immune in the 2nd quarter valued at approximately $56,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock worth $72,000 after buying an additional 7,400 shares in the last quarter. Hedge funds and other institutional investors own 51.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. StockNews.com cut shares of AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of AC Immune in a research report on Wednesday, September 18th.

AC Immune Stock Performance

Shares of NASDAQ:ACIU traded down $0.04 during midday trading on Wednesday, reaching $2.97. The company had a trading volume of 66,699 shares, compared to its average volume of 354,586. The company has a fifty day simple moving average of $3.28 and a two-hundred day simple moving average of $3.43. The firm has a market cap of $293.73 million, a price-to-earnings ratio of -4.36 and a beta of 1.25. AC Immune has a 1-year low of $2.25 and a 1-year high of $5.14.

AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. Analysts expect that AC Immune will post -0.89 EPS for the current year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.